Search

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

86.17 -1.88

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

85.57

Максимум

88.32

Ключови измерители

By Trading Economics

Приходи

-49M

-105M

Продажби

11M

71M

EPS

-0.73

Марж на печалбата

-147.27

Служители

414

EBITDA

6.2M

-44M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+66.4% upside

Дивиденти

By Acuity

Следващи печалби

3.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-1B

6B

Предишно отваряне

88.05

Предишно затваряне

86.17

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.10.2026 г., 20:07 ч. UTC

News

Rhythm Pharmaceuticals receives an Overweight rating from JPMorgan, with the price target adjusted to $145.00, reflecting a continued positive outlook.

14.10.2026 г., 19:56 ч. UTC

News
Event

Rhythm Pharmaceuticals Inc launched IMCIVREE in Japan as the first approved therapy for acquired hypothalamic obesity, supported by Phase 3 TRANSCEND trial data.

13.10.2026 г., 22:11 ч. UTC

Correlated Moves

Rhythm Pharmaceuticals Inc shares advanced modestly in after-market trading, correlating with slight gains in the Direxion Daily S&P Biotech Bull 3X ETF.

12.10.2026 г., 19:46 ч. UTC

Rhythm Pharmaceuticals Inc shares fell, fluctuating within a routine range and remaining significantly below its 20-day moving average.

9.10.2026 г., 20:07 ч. UTC

Social Media

Rhythm Pharmaceuticals shares advanced after BofA set a new price target of $150, supported by positive feedback on its MC4R franchise for adult hypothalamic obesity.

8.10.2026 г., 20:01 ч. UTC

News

RBC Capital raises Rhythm Pharmaceuticals price target to $159.00 from $155.00 while maintaining an Outperform rating, citing strong market performance over five years.

7.10.2026 г., 19:25 ч. UTC

Rhythm Pharmaceuticals Inc shares fell sharply, remaining well below their 20-day moving average and significantly lower compared to Tuesday's close.

6.10.2026 г., 20:30 ч. UTC

Rhythm Pharmaceuticals Inc is experiencing a significant decline in after-market trading, moving further below its 20-day moving average since Tuesday's close.

5.10.2026 г., 20:30 ч. UTC

Rhythm Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of six consecutive daily declines and remaining below its 20-day moving average.

2.10.2026 г., 20:07 ч. UTC

Rhythm Pharmaceuticals Inc shares fell sharply, continuing a downward trend with four consecutive sessions in the red and remaining below the 20-day moving average.

1.10.2026 г., 20:13 ч. UTC

Rhythm Pharmaceuticals Inc is advancing in after-market trading, gaining ground since Thursday's close while currently trading below its 20-day moving average.

29.09.2026 г., 20:07 ч. UTC

Rhythm Pharmaceuticals Inc shares fell sharply, declining notably from Monday's close and trading well below its 20-day moving average amid ongoing pressure.

24.09.2026 г., 19:25 ч. UTC

Rhythm Pharmaceuticals Inc shares fell modestly, currently near the lower end of their one-month range and below the 20-day moving average amid broader market weakness.

23.09.2026 г., 22:25 ч. UTC

Rhythm Pharmaceuticals Inc is rising in after-market trading, recovering from an initial dip and advancing since Wednesday's close, though still below its 20-day moving average.

22.09.2026 г., 20:07 ч. UTC

Event
Correlated Moves
News

Rhythm Pharmaceuticals' IMCIVREE® received Health Canada approval for weight management in patients with acquired hypothalamic obesity, boosting shares higher during the session.

21.09.2026 г., 20:06 ч. UTC

Rhythm Pharmaceuticals Inc is higher today, continuing an upward trend since Friday, despite mid-morning volatility and remaining below its 20-day moving average.

18.09.2026 г., 20:06 ч. UTC

Rhythm Pharmaceuticals Inc shares fell sharply, settling near the lower end of their one-month range and significantly below the 20-day moving average.

17.09.2026 г., 20:07 ч. UTC

Correlated Moves

Rhythm Pharmaceuticals advances during Thursday's session, boosted by a rally in the biotechnology sector following positive Phase 3 results for Moderna's cancer vaccine.

16.09.2026 г., 20:10 ч. UTC

Rhythm Pharmaceuticals Inc is experiencing an upward movement during Wednesday's trading session, recovering from an early low with a peak return of 4.17%.

15.09.2026 г., 20:01 ч. UTC

News

Rhythm Pharmaceuticals shares are lower amid concerns from CEO insider selling and a drop in the NY Empire State Manufacturing Index for September.

14.09.2026 г., 20:08 ч. UTC

Rhythm Pharmaceuticals Inc. shares are lower today, continuing a decline since Friday's close, despite an earlier rebound from session lows.

11.09.2026 г., 19:52 ч. UTC

Rhythm Pharmaceuticals shares are higher during Friday's session, pulling back from earlier gains. No specific news was identified to explain the movement.

8.09.2026 г., 20:08 ч. UTC

Correlated Moves

RYTM trades lower as the biotech sector faces pressure.

2.09.2026 г., 20:08 ч. UTC

News

Rhythm Pharmaceuticals is higher today, supported by gains in the Biotechnology sector and CFO share transactions that reflect confidence in future performance.

1.09.2026 г., 19:26 ч. UTC

News

Rhythm Pharmaceuticals reported a net loss of -$33.26 million on revenue of $17.28 million. Shares are lower, continuing a trend of three consecutive sessions finishing down.

31.08.2026 г., 23:46 ч. UTC

Rhythm Pharmaceuticals Inc shares rose in after-market trading, reflecting a gradual increase from earlier lows, though still below the 20-day moving average.

28.08.2026 г., 20:02 ч. UTC

News

Rhythm Pharmaceuticals Inc shares are lower as Deutsche Bank initiates coverage with a Hold rating and a price target of $120.

26.08.2026 г., 20:08 ч. UTC

News

Rhythm Pharmaceuticals is trading lower, influenced by declines in the Biotechnology sector and a broader market downturn since Tuesday's close.

25.08.2026 г., 21:02 ч. UTC

Rhythm Pharmaceuticals Inc shares are lower in after-market hours. No specific news was identified to explain the decline, contrasting recent upward trends.

21.08.2026 г., 19:36 ч. UTC

Rhythm Pharmaceuticals Inc shares are higher during Friday's session, reflecting positive market response. The stock reached a session high earlier before pulling back.

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

66.4% нагоре

12-месечна прогноза

Среден 146.385 USD  66.4%

Висок 206 USD

Нисък 120 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

14

Купи

1

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat